November 18, 2016

Long-Term Analysis of All 695 Patients Enrolled in Novocure’s Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Confirms Successful Interim Analysis Results and Demonstrates Superior Two- and Four-Year Survival Rates

Patients treated with Optune® together with temozolomide demonstrated a significant increase in progression free and overall survival compared to patients treated with temozolomide alone EF-14 patients treated with Optune together with temozolomide experienced a 70 percent improvement in survival rate at four years compared to… Read More
learn more
November 17, 2016

Novocure Presents Interim STELLAR Results at IASLC Suggesting Treatment with Tumor Treating Fields Plus Chemotherapy may Extend Survival of Patients with Mesothelioma

One-year survival rates of patients treated with Tumor Treating Fields combined with pemetrexed and cisplatin or carboplatin were more than 58% greater than historical control data No device-related serious adverse events have been reported to date November 17, 2016 07:30 AM Eastern Standard Time… Read More
learn more
November 14, 2016

Novocure Sponsors Pulitzer Prize-Winning Author Dr. Siddhartha Mukherjee as Keynote Speaker of 21st Annual Scientific Meeting of the Society for Neuro-Oncology

Dr. Mukherjee wrote Pulitzer Prize-Winning book The Emperor of All Maladies and New York Times bestseller The Gene. Novocure has sponsored Pulitzer Prize-winning author Dr. Siddhartha Mukherjee as the keynote speaker of 21st Annual Scientific Meeting of the Society for Neuro-Oncology on… Read More
learn more
November 7, 2016

Novocure Announces 38 Presentations on Tumor Treating Fields at 21st Annual Scientific Meeting of the Society of Neuro-Oncology

28 of 38 abstracts were prepared by external researchers, representing increasing interest in Novocure’s proprietary therapy The long-term analysis of all 695 patients enrolled in its phase 3 pivotal trial in newly diagnosed GBM which confirms the superior progression free and overall survival seen in… Read More
learn more
November 3, 2016

United Healthcare Issues Positive Coverage Decision for Optune

As of Jan. 1, 2017, more than 177 million Americans will have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma November 03, 2016 07:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that United Healthcare will cover Optune… Read More
learn more
November 2, 2016

Novocure Reports Third Quarter 2016 Financial Results and Provides Company Update

Continued growth in active patients with 985 active patients at September 30, 2016, an increase of 110 percent from September 30, 2015, and 11 percent from June 30, 2016 Third quarter 2016 reported revenues of $21.7 million, reflecting 142 percent growth versus third quarter 2015 and 21… Read More
learn more
November 1, 2016

Novocure Recognizes National Family Caregivers Month by Supporting GBM Heroes Event

November 01, 2016 04:05 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will promote programs that support the glioblastoma (GBM) community during National Family Caregivers Month in November. Novocure will sponsor CURE magazine’s 2nd Annual GBM Heroes Recognition program, which honors those… Read More
learn more